Aureon Laboratories to Collaborate with Pfizer

Aureon Laboratories, Inc. has announced a new phase in a research collaboration with Pfizer, Inc. that shall establish quantitative biometrics for assessing therapeutic response derived from studies focusing on prostate cancer.

The collaboration will utilize Aureon’s integrated systems pathology approach, whereby data generated from tissue morphometry, multiplexed-protein biomarkers, and in situ RNA expression are integrated with patient clinical information and associated with clinical outcome.

The collaboration is an extension of a previous study performed by Aureon and Pfizer to evaluate prostatectomy samples from patients treated with neo-adjuvant androgen deprivation therapy (ADT).

The previous project also demonstrated the technical feasibility of Aureon’s platform in quantifying T-cell subtypes in a lymphoid infiltrate and the cellular distribution of cytokines using intact formalin-fixed, paraffin-embedded (FFPE) tissue specimens.

Vijay Aggarwal, PhD, CEO and President of Aureon Laboratories said, “We are very excited about collaborating with Pfizer on the next phase of this research project. Aureon’s ability to integrate and quantify histological features and cell-type specific molecular biomarkers in intact paraffin-embedded tissue allows a better understanding of the biological context in terms of assessing therapeutic response.”